Background: Intestinal obstruction and constipation are common conditions in patients with advanced neoplasms. Diatrizoate Meglumine has been used in the management of both these conditions without good quality evidence of its effectiveness and safety. Aim: This audit aimed to assess the usage, effectiveness and adverse effects of Diatrizoate Meglumine for intestinal obstruction and constipation in patients with advanced neoplasms. Design: A retrospective chart review was undertaken. Descriptive statistics were utilised.
Background
Diatrizoate Meglumine (Gastrografin ® ) is an oral watersoluble contrast agent that has primarily been used as a diagnostic aid to radiologic examination. It may exhibit a therapeutic effect in small intestinal obstruction by reducing the intestine wall oedema and increasing intraluminal tension 1 and may be of benefit in the management of inoperable intestinal obstruction and constipation in patients with advanced neoplasms. [2] [3] [4] Intestinal obstruction has a prevalence of 3%-15% in cancer patients 5 and can cause significant physical distress. The most common diagnoses are ovarian neoplasms (20%-50%) and colorectal neoplasms (10%-28%). 2 Guidelines for the management of intestinal obstruction in patients with advanced neoplasms lack an adequate evidence base despite the frequency of this condition. 6 The current palliative management of intestinal obstruction commonly involves a combination of analgesia, anti-emetics, anti-secretory drugs and corticosteroids. 7 Finding effective medications for the management of inoperable intestinal obstruction has been challenging. Octreotide does not improve days free of vomiting in intestinal obstruction 7 while a phase-II study of Gastrografin failed to recruit enough patients to proceed to a phase-III study. 6 A retrospective review of the use of Diatrizoate Meglumine in patients with small intestinal obstruction with concurrent abdominal/pelvic neoplasms found that Diatrizoate Meglumine was safe, effective and has the potential to improve quality of life in patients with lifelimiting disease. 4 Diatrizoate Meglumine could potentially cause aspiration pneumonitis, dehydration and hypersensitivity reactions. 10 A Cochrane review 11 and other studies have found Diatrizoate Meglumine to be safe in patients with adhesive small bowel obstruction who do not have clinical evidence of bowel ischaemia. 1, 8, 12 While most studies have used 100 mL of Diatrizoate Meglumine as an intervention dose, [13] [14] [15] [16] [17] the doses generally used in clinical practice are unknown.
Anecdotally, Diatrizoate Meglumine has also been used in resistant constipation in patients with advanced neoplasms. There is very little literature around this indication.
This retrospective audit aims to explore the usage, effectiveness and adverse effects of Diatrizoate Meglumine in patients with advanced neoplasms. This preliminary data will help guide future controlled studies of Diatrizoate Meglumine use in this population.
Patients and methods
A retrospective clinical chart review was undertaken on all patients with advanced neoplasms who were admitted to Mater Health Services and St Vincent's Private Hospital Brisbane between January 2013 and October 2015 (approximately 34 months) and were administered oral Diatrizoate Meglumine. These patients were identified through a pharmacy database that records the prescription of Diatrizoate Meglumine. Only the hospital pharmacist had access to this database. No participants were involved in this retrospective audit. Therefore, no participant consent was sought, as part of ethical approval.
A peer-reviewed data collection form was used. Data were collected on basic demography and clinical parameters including when Diatrizoate Meglumine was used for intestinal obstruction or constipation. Intestinal obstruction was defined as clinical evidence of intestinal obstruction via history and physical examination or radiographic evidence. Constipation was defined as fewer than three bowel movements a week with stools that were hard and difficult to pass.
Data were also collected on dose of Diatrizoate Meglumine delivered, use of imaging, clinical resolution of intestinal obstruction by passage of stool and ability to tolerate oral intake for more than 48 h and resolution of constipation (defined as easy passage of soft stool).
Data were entered into a password-protected database and analysed by descriptive statistics. 
Results
A total of 71 patients were administered Diatrizoate Meglumine between January 2013 and October 2015 of which 24 were males and 47 were females. The average age was 63 years (range: 29-93).
The most common diagnoses were ovarian or primary peritoneal neoplasms (33.8%). Diatrizoate Meglumine was used for intestinal obstruction in 42 (59.2%) patients (Table 1) .
Implications for practice, theory or policy 1. Diatrizoate Meglumine was found to be safe and well tolerated in patients with advanced neoplasms. 2. This paper assists in writing guidelines for usage of Diatrizoate Meglumine in patients with advanced neoplasms.
The median dose administered was 50 mL as a single dose, but the doses varied from 15 to 500 mL. The higher doses were given as repeated small doses over several days.
Most patients underwent imaging prior to administration of Diatrizoate Meglumine. Forty-one (57.8%) patients had repeat imaging post-dose (Table 2) . Of those who did not, all but one had resolution of their intestinal obstruction or constipation. Thirty-two patients had repeat imaging between 4 and 24 h post-dose, and Diatrizoate Meglumine could be seen in the large bowel in 75% of these images.
All patients with constipation had resolution of their constipation. Eighteen patients with constipation were on dexamethasone.
Intestinal obstruction took longer to resolve. Twentynine resolved 2 days after administration of Diatrizoate Meglumine, while six patients took more than 2 days. Of those who had resolution, 22 patients were on dexamethasone while 11 were not. In seven patients (10%), the intestinal obstruction did not resolve (Table 3 ). All seven were on dexamethasone.
The most common symptom attributable to administration of Diatrizoate Meglumine was diarrhoea affecting 10 (14%) patients. There were no reports of aspiration pneumonia or hypersensitivity.
Three patients died within 1-2 days of administration of Diatrizoate Meglumine. Their history was reviewed by independent clinicians who deemed that the deaths were due to underlying disease progression, and not Diatrizoate Meglumine.
Discussion
Diatrizoate Meglumine has been used in an attempt to improve symptoms and resolve intestinal obstruction and constipation in patients with advanced neoplasms.
In this study, the most common diagnosis of patients who received Diatrizoate Meglumine was ovarian or primary peritoneal neoplasms. This is in line with other studies showing that 20%-50% of patients with ovarian neoplasms present with symptoms of intestinal obstruction at some stage of their disease. 2 The dose of Diatrizoate Meglumine administered varied widely as there were no adequate guidelines. Thirty-five (49%) patients had 50 mL of Diatrizoate Meglumine administered as a single dose. Pharmacy product information advises a maximum of 100 mL of Diatrizoate Meglumine for a follow-through examination of the gastrointestinal tract. 10 Neither intestinal obstruction nor constipation was listed as an indication for Diatrizoate Meglumine. While most patients had imaging prior to Diatrizoate Meglumine administration, a small number (11/71) did not. A recent review concluded that a plain abdominal x-ray is usually sufficient in most cases. However, a computed tomography (CT) scan should be considered in patients in whom the extent of neoplasm is unknown or when the intestinal obstruction may benefit from operative intervention. 5 There is even less evidence guiding the timing of imaging after Diatrizoate Meglumine. A Cochrane review in adhesive small intestinal obstruction was not able to advise the optimal timing of imaging. 11 In this study, approximately half of the patients had repeat imaging within 4-24 h, with Diatrizoate Meglumine identified in the large bowel in 75% of cases.
In patients who had intestinal obstruction, 84% resolved following Diatrizoate Meglumine. However, spontaneous resolution occurs in 31%-42% of patients with inoperable intestinal obstruction. 5 While the resolution rate in this audit was higher than previous published studies, 5, 18 it is still not possible to solely attribute this to Diatrizoate Meglumine as other medications were used that may speed the resolution of intestinal obstruction, for example, dexamethasone and ranitidine. 7 In this study, Diatrizoate Meglumine was found to be safe to use. There were no hypersensitivity reactions and no incidence of aspiration pneumonia which is a recognised rare complication (<1/1000). 9 This is consistent with a Cochrane review that found Diatrizoate Meglumine to be safe. 11 A Cochrane review of laxatives for the management of constipation in people receiving palliative care concluded that the different laxatives reviewed appeared to be of similar effectiveness, but there was limited evidence due to insufficient data from only a few small randomised controlled trials. 19 Diatrizoate Meglumine was not reviewed in the study. Another Cochrane review in patients with adhesive small bowel obstruction concluded that Diatrizoate Meglumine did not cause resolution of small bowel obstruction but appeared to reduce length of hospital stay. 11 This was not specifically in the palliative care setting. In contrast, Diatrizoate Meglumine seemed effective for constipation and malignant bowel obstruction in this study but it is a retrospective audit. Higher quality studies are needed to be included in future Cochrane reviews.
Conclusion
There is little evidence in the literature on Diatrizoate Meglumine in patients with advanced neoplasms despite relatively common use in everyday practice. This retrospective audit found Diatrizoate Meglumine was associated with the resolution of intestinal obstruction and constipation. This study will guide the dose delivered and timing of imaging to be used in subsequent randomised placebo-controlled trials that are needed to further inform the effectiveness and safety of Diatrizoate Meglumine in patients with advanced neoplasms.
